1 MD, Professor, Liver and Gastrointestinal Diseases Research Center, Tabriz Cystic Fibrosis Registry, Tabriz University of Medical Sciences, Tabriz, Iran.

2 PhD, Assistant Professor, Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

3 MSc, Nutrition Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.

4 MD, Department of Pediatrics, Tabriz University of Medical Sciences, Tabriz, Iran.

5 Ph.D, Assistant Professor, Liver and Gastrointestinal Diseases Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.


Background: Cystic fibrosis (CF) is one of the most common genetic disorders in children. CF patients are susceptible to chronic lung infections and malabsorption. Although patient longevity is increased by multidisciplinary care, patients still suffer from respiratory failure and low quality of life. In this situation, CF patients tend to use complementary treatments. To the best of our knowledge there is no research about curcumin supplementation in CF patients; thus, we decided to investigate the effects of curcumin supplementation on anthropometric indices, and quality of life in children with cystic fibrosis.
Materials and Methods
This randomized control-controlled clinical study was conducted in Tabriz University of Medical Sciences, Iran. Forty CF patients were randomly sorted into intervention (n=20), and control (n=20) groups. Patients received 3 curcumin nanoparticles (80 mg; total dose 240 mg/d) for six consecutive months. Before and after intervention, height and weight were measured and quality of life of patients was evaluated by the Pediatric Quality of Life Inventory (PedsQL) 4.0 (CITE). 
Results: After intervention, the percentage of weight changes showed a significant increase in the curcumin group compared to the control group (7.48±4.68 vs. 4.15±4.68 kg, p=0.03). Following the intervention, only the percentage of change in emotional functioning scores was significant (p=0.01).  Subjects in the curcumin group showed a trend towards more improvement in terms of percentage change in physical functioning (19.28±31.65 vs.  15.24±47.14), and school functioning scores (40.96±42.93 vs 23.90±14.82) compared with the control group. 
Our findings suggest that curcumin may be a useful, inexpensive, and safe supplement in combination with conventional therapy to improve body weight in CF children.


  1. Foundation CF. Patient Registry Report. Bethesda,

MD: Cystic Fibrosis Foundation. Accessed October 26, 2010.;


  1. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95(7):1005-15.
  2. Haq IJ GM, Garnett JP, Ward C, Brodlie M. Airway surface liquid homeostasis in cystic fibrosis: Pathophysiology and therapeutic targets. Thorax. 2016;71:3.
  3. Bradbury N. Cystic Fibrosis. In: Bradshaw, RD.; Stahl, P., editors. The encyclopedia of cell biology. Elsevier. 2015:10.
  4. Cantin AM. Potential for antioxidant therapy of cystic fibrosis. Current Opin Pulmonary Med. 2004;10(6):531-6.
  5. Chmiel JF, Konstan MW. Anti-inflammatory medications for cystic fibrosis lung disease. Treatment Respiratory Med. 2005;4(4):255-73.
  6. Tanase A, Zanni R. The use of complementary and alternative medicine among pediatric cystic fibrosis patients. J Alter Complement Med. 2008;14(10):1271-3.
  7. Borowitz D, Parad R, Sharp J, Sabadosa K, Robinson K, Rock M, et al. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr. 2009;155(suppl 6):S106-16.
  8. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183(11):1463-71.
  9. Martin C, Hamard C, Kanaan R, Boussaud V, Grenet D, Abély M, et al. Causes of death in French cystic fibrosis patients: the need for improvement in transplantation referral strategies! J Cystic Fibrosis. 2016;15(2):204-12.
  10. Abdulhamid I, Beck F, Millard S, Chen X, Prasad A. Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonol 2008;43(3):281-7.
  11. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alter Med Rev. 2009;14(2).
  12. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195-218.
  13. Reverri EJ, Morrissey BM, Cross CE, Steinberg FM. Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis. Free Radical Biol Med. 2014;76:261-77.
  14. Khdair SA, Abdulridha MK, Fatah MA. Effect of Curcumin Supplement on Pulmonary Functions, Total and Differential White Blood Cell Count, Serum Level of Leptin and Body Mass Index in a Sample of Iraqi Patients with Chronic Bronchial Asthma. AJPS. 2019;19(2):47-58.
  15. Chaudhary N, Ueno-Shuto K, Ono T, Ohira Y, Watanabe K, Nasu A, et al. Curcumin down-regulates toll-like receptor-2 gene expression and function in human cystic fibrosis bronchial epithelial cells. Biol Pharmaceutical Bull. 2019:b18-00928.
  16. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502-6.
  17. Zhang X, Chen Q, Wang Y, Peng W, Cai H. Effects of curcumin on ion channels and transporters. Frontiers in physiology. 2014;5:94.
  18. Berger AL, Randak CO, Ostedgaard LS, Karp PH, Vermeer DW, Welsh MJ. Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl–channel activity. J BiolChem. 2005;280(7):5221-6.
  19. Varni JW, Burwinkle TM, Seid M, Skarr DJAp. The PedsQL™ 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambulat Pediatr. 2003;3(6):329-41.
  20. Varni JW, Seid M, Kurtin PSJMc. PedsQL™ 4.0. Reliability and validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in healthy and patient populations. Med Care. 2001;39(8):800-12.
  21. Amiri P, Eslamian G, Mirmiran P, Shiva N, Jafarabadi MA, Azizi F. Validity and reliability of the Iranian version of the Pediatric Quality of Life Inventory™ 4.0 (PedsQL™) Generic Core Scales in children. Health Quality Life Outcome. 2012;10(1):3.
  22. Amiri P, Ardekani EM, Jalali-Farahani S, Hosseinpanah F, Varni JW, Ghofranipour F, et al. Reliability and validity of the Iranian version of the Pediatric Quality of Life Inventory™ 4.0 Generic Core Scales in adolescents. Qulaity Life Res. 2010;19(10):1501-8.
  23. Dey I, Shah K, Bradbury NA. Natural compounds as therapeutic agents in the treatment cystic fibrosis. J Genetic Syndromes Gene Therapy. 2016;7(1).
  24. Song Y, Sonawane N, Salinas D, Qian L, Pedemonte N, Galietta LJ, et al. Evidence against the rescue of defective ΔF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem. 2004;279(39):40629-33.
  25. He Z-Y, Shi C-B, Wen H, Li F-L, Wang B-L, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 2011;29(3):208-13.
  26. Olveira G, Olveira C, Acosta E, Espíldora F, Garrido-Sánchez L, García-Escobar E, et al. Fatty acid supplementation improves respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Archiv Bronconeumología ((English Edition)). 2010;46(2):70-7.
  27. Alipour M, Omri A, Suntres ZE. Ginseng aqueous extract attenuates the production of virulence factors, stimulates twitching and adhesion, and eradicates biofilms of Pseudomonas aeruginosa. Canad J Physiol Pharmacol. 2011;89(6):419-27.